UNIT 5.23 Characterization of Matrix Metalloproteinase Inhibitors: Angiogenesis and Tumor Models
Published Online: 1 AUG 2001
Copyright © 2003 by John Wiley and Sons, Inc.
Lab Protocol Title
Current Protocols in Pharmacology
How to Cite
Albert, D. H. and Davidsen, S. K. 2001. Characterization of Matrix Metalloproteinase Inhibitors: Angiogenesis and Tumor Models. Current Protocols in Pharmacology. 13:5.23:5.23.1–5.23.12.
- Published Online: 1 AUG 2001
- Published Print: JUN 2001
Since the matrix metalloproteinases (MMPs) have an essential role in the process of tumor growth, invasion and metastasis, small molecule MMP inhibitors have the ability to modulate tumor progression in animals and the potential to be of therapeutic benefit to cancer patients. The antiangiogenic properties of MMP inhibitors can be assessed by the measurement of hemoglobin content of Matrigel plugs containing angiogenic growth factors introduced into the flanks of mice. A flank tumor growth model using B16 murine melanoma cells provides a useful means of determining the antitumor effects of MMP inhibitors as well as correlating efficacy with the concentration of drug in blood.